A Phase 1/2 Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of an Intravitreal Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular Age-related Macular Degeneration
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 17 Aug 2017
At a glance
- Drugs GB 102 (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Sponsors GrayBug inc.
- 10 Aug 2017 Status changed from planning to not yet recruiting.
- 08 May 2017 Accoridng to GrayBug media release, this study will be initiated in Q3 2017.
- 04 May 2016 New trial record